Auricular Neuromodulation for Sinus Surgery
What You Need to Know Before You Apply
What is the purpose of this trial?
In this blinded prospective randomized control trial the researchers will investigate the impact of cutaneous vagal nerve stimulation on surgical conditions in patients undergoing functional and ascorbic sinus surgery (FESS). The device is an externally placed vagal nerve stimulator. The device will be applied to participants after consent and induction of anesthesia. The study team will open the randomization envelope and if the participant is assigned to stimulation the device will be turned on. In the case that the participant is assigned to the control arm, the device will be set to sham. The device will remain on for 30 minutes and removed before entering the OR. Device will be reinserted in the recovery room for another 30 minutes.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you've used anti-fibrinolytic drugs within 30 days before enrolling.
Is auricular neuromodulation safe for humans?
Auricular neuromodulation, also known as transcutaneous auricular vagus nerve stimulation (taVNS), is generally considered safe with only mild and temporary side effects like ear pain, headache, and tingling. Studies show no significant risk of severe adverse events, making it a safe option for clinical use.12345
How is auricular neuromodulation different from other treatments for sinus surgery?
Auricular neuromodulation is unique because it uses non-invasive electrical stimulation of the ear to activate the vagus nerve, which can influence brain and body functions without the need for surgery or drugs. This method targets specific areas of the ear to modulate nerve activity, offering a novel approach compared to traditional treatments that may involve medication or surgical intervention.46789
What data supports the effectiveness of the treatment Auricular Neuromodulation for Sinus Surgery?
Research shows that auricular vagus nerve stimulation (AVNS) is being explored for various conditions like heart failure and migraines, suggesting its potential to influence bodily functions. Although specific data for sinus surgery is limited, the technique's ability to modulate the nervous system non-invasively indicates promise for broader therapeutic applications.45678
Who Is on the Research Team?
Daniel Katz, MD
Principal Investigator
MOUNT SINAI HOSPITAL
Are You a Good Fit for This Trial?
This trial is for healthy individuals (ASA 1 and 2) scheduled for elective sinus surgery (FESS). It's not open to those with pacemakers, cochlear implants, neurostimulators, clotting disorders, obesity, smokers, pregnant women, recent blood transfusions or anti-fibrinolytic drug use, ear infections or abnormalities.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo functional endoscopic sinus surgery with the application of the neuromodulation device for 30 minutes before and after surgery
Follow-up
Participants are monitored for post-operative outcomes such as nausea, vomiting, and pain in the PACU
Long-term follow-up
Participants are monitored for any long-term effects or complications post-surgery
What Are the Treatments Tested in This Trial?
Interventions
- Auricular Neuromodulation
Auricular Neuromodulation is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Icahn School of Medicine at Mount Sinai
Lead Sponsor